BioSpace News Archive

First of Its Kind HCPCS Level II Code is a Breakthrough for Access to Exoskeletons for Individuals with Spinal Cord Injury Company Will Seek Coverage Policies with U.S. National, State and Private Payors.

Piclidenoson to be evaluated for the treatment of COVID-19 infected patients with moderate symptoms

OMRON Healthcare, Inc., the global leader in personal heart health and wellness technology, and Mount Sinai Health System, New York City’s largest academic medical system, have teamed together to offer patients the new VitalSight™ home blood pressure monitoring solution.

Achieving 30x exposure in lungs at significantly lower dose while reducing systemic and cardiac toxicities

-Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020- -Trogarzo ® net revenues up 13.2% and combined EGRIFTA ® , EGRIFTA SV ® net revenues up 7.3% over Q2 2019- -Supply chain and product inventory remain unaffected by COVID-19 pandemic- MONTREAL, July 15, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2020 financial results on Thursday, July 30, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2020. The conference call will be accessible by dialing toll-free (844)

Preliminary Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020

Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continu

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields together with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatment of non-small cell lung cancer (NSCLC). Novocure’s Tumor Treating Fields use electric fields tuned to specific frequencies to disrupt cell di

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of July 2020, which is payable on August 17, 2020 to shareholders of record at the close of business on July 31, 2020